Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bacterial Infections

Bacterial Infections

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bacterial Infections

47 trials tracked for Bacterial Infections: 21 in phase 3 or 4 and 10 with published results. The most-cited published study has 413 citations.

47Trials tracked
21Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 6 Phase 3 15 Phase 2 10 Phase 1 12 Other / NA 4
  1. Phase 3 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) Completed · 413 cited
  2. Phase 3 Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI Completed · 95 cited
  3. Phase 3 Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Completed · 48 cited
  4. Phase 3 Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23) Completed · 46 cited
  5. Phase 3 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) Completed · 42 cited
  6. Phase 4 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Completed · 39 cited
Show 41 more trials
  1. Phase 3 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) Completed · 34 cited
  2. Phase 4 Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed Completed · 24 cited
  3. Phase 3 A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) Completed · 24 cited
  4. Phase 3 Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) Completed · 16 cited
  5. Phase 4 Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers Completed
  6. Phase 4 A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Completed
  7. Phase 4 Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery Completed
  8. Phase 4 Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers Completed
  9. Phase 3 Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Completed
  10. Phase 3 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Completed
  11. Phase 3 Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Completed
  12. Phase 3 Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Completed
  13. Phase 3 Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis. Completed
  14. Phase 3 Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Completed
  15. Phase 3 Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) Completed
  16. Phase 2 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections Completed
  17. Phase 2 A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia Completed
  18. Phase 2 Study of Debio 1450 for Bacterial Skin Infections Completed
  19. Phase 2 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age Completed
  20. Phase 2 MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection Completed
  21. Phase 2 Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Completed
  22. Phase 2 Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Completed
  23. Phase 2 Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus Completed
  24. Phase 2 Effect of Xylitol on Oral Microbiota in Children Completed
  25. Phase 2 Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis) Completed
  26. Phase 1 Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile Completed
  27. Phase 1 Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects Completed
  28. Phase 1 Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions Completed
  29. Phase 1 Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections Completed
  30. Phase 1 Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function Completed
  31. Phase 1 Amoxicillin Bioequivalence Study Brazil - Fast Completed
  32. Phase 1 To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects. Completed
  33. Phase 1 Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function Completed
  34. Phase 1 To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Completed
  35. Phase 1 A Study To Assess The Effect Of Linezolid On QTc Interval Completed
  36. Phase 1 Drug-drug Interaction Study of Gepotidacin Completed
  37. Phase 1 Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects Completed
  38. N/A Adjunctive Steps for Disinfection of Teeth With Primary Endodontic Infections Completed
  39. N/A Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan) Completed
  40. N/A Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF Completed
  41. N/A French Study In ICU Patients Treated With Tigecycline Completed

Showing the 47 most-cited and recently-updated of 47 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Bacterial Infections: what the trials found

Dalbavancin was associated with a significant reduction in both infection-related total admitted hospital days (4.8 vs. 3.2, p=0.003) and total admitted hospital days (4.9 vs. 3.2, p=0.003) 2. In clinical response assessments at 48-72 hours, Dalbavancin demonstrated high rates of clinical response (96.5% to 98.6%) and microbiological response in specific cohorts 16.

Vaccination trials showed significant immunogenicity for various pathogens. The V419 vaccine demonstrated high percentages of participants with acceptable antibody responses to Haemophilus Influenzae type b, Diphtheria, Tetanus, and Poliovirus types 1, 2 & 3 13, as well as response to Polyribosylribitol Phosphate (84.97% to 97.25%, p<0.001) and Hepatitis B Surface Antigen (98.58% to 99.42%, p<0.001) 18. The PR5I vaccine showed high seroresponse rates for all antigens, including a statistically significant superiority in antibody response to Haemophilus Influenzae type b compared to INFANRIX Hexa [12, 13, 15].

Other interventions included Tedizolid, which showed no significant difference in early clinical response at 48-72 hours (75.3% vs. 79.9%, p=0.2027) but demonstrated high rates of investigator-assessed clinical success at post-therapy evaluation 10. Tigecycline was evaluated for clinical cure versus failure over a period of 25-27 weeks post-last dose 22.

Recent results — preliminary, needs further review

  • [ ] Omadacycline (Nuzyra) is currently in Phase 1 investigation 1.

For the clinician treating this condition

  • Dalbavancin significantly reduces the number of hospital days for patients with infections compared to standard care 2.
  • Vaccine interventions like V419 and PR5I demonstrate high efficacy in inducing antibody responses against multiple pathogens including H. influenzae, Diphtheria, Tetanus, and Poliovirus [12, 13, 18].
  • Tedizolid showed consistent clinical success rates at post-therapy evaluation despite no significant difference in early response compared to the control group 10.

AI synthesis of 7 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of influenza A and secondary bacterial infections identifies critical knowledge gaps
Infectious Disease Sys. Review
Review of influenza A and secondary bacterial infections identifies critical knowledge gaps Review highlights gaps in flu and secondary infection care
This is a narrative review on influenza A virus infection, secondary bacterial infection, and nosocomial infection. The authors synthesize c…
A new review points out major missing knowledge about flu and related infections. It calls for more research to help patients.
Frontiers May 25, 2026
Systematic Review Explores Ubiquitination in Bacterial Infection and Immune Response
Gastroenterology Sys. Review
Systematic Review Explores Ubiquitination in Bacterial Infection and Immune Response Your Body Has a Hidden Weapon Against Superbugs
This systematic review synthesizes evidence on the role of ubiquitination in bacterial infections. It describes how the ubiquitination syste…
Your immune system uses a natural "tagging" process to mark invading bacteria for destruction, and scientists now understand how to make thi…
Frontiers May 12, 2026
Nasopharyngeal swab tNGS shows high bacterial concordance with BALF in ICU pneumonia
Infectious Disease Cohort
Nasopharyngeal swab tNGS shows high bacterial concordance with BALF in ICU pneumonia Nasal swabs can spot key pneumonia germs in ICU patients when lung tests aren't ready
This prospective observational cohort study in 105 critically ill ICU patients found high concordance between nasopharyngeal swab (NPS) and…
For critically ill pneumonia patients, a quick nasal swab can often match the gold-standard lung test for major bacteria, offering a faster …
Frontiers Apr 22, 2026
Meta-analysis finds no significant difference in outcomes between high- and low-dose ceftriaxone for non-CNS infections
Infectious Disease Meta-analysis
Meta-analysis finds no significant difference in outcomes between high- and low-dose ceftriaxone for non-CNS infections Do higher doses of a common antibiotic help adults with infections?
A meta-analysis of eight studies involving 5145 adults with non-CNS infections found no statistically significant difference in clinical cur…
Higher doses of the antibiotic ceftriaxone show no clear benefit over the standard 1-gram daily dose for curing infections in adults, based …
Apr 2, 2026

Questions about Bacterial Infections

Do different doses of ceftriaxone change the hospital stay for bacterial infections?

A meta-analysis found no significant difference in hospital length of stay between high-dose and low-dose ceftriaxone for non-CNS infections.

Full answer →